US equities |
SPCX $167.41 ▲+5.32% NVDA $236.50 ▲+1.09% MU $1,068.48 ▼-0.60% TSLA $378.87 ▲+2.23% MSFT $526.31 ▲+1.70% SNDK $1,713.01 ▼-0.41% INTC $117.13 ▼-1.84% META $744.71 ▲+2.28%
FinancialContent

Gyre Therapeutics, Inc. - Common Stock (NQ:GYRE)

7.290 +0.180 (+2.53%)
Delayed Quote Updated: 12:47 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gyre Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Gyre Therapeutics to Participate in Upcoming September Investor Conferences
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Appoints Three New Members to its Board of Directors
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead ↗
Pulmatrix said that Cullgen notified it of the termination of the deal between them on Feb. 28. 
Via Stocktwits
News headline image
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Inc (NASDAQ:GYRE) Reports Q3 2025 Earnings Beat Amid Revenue Miss and Lowered Guidance ↗
Gyre Therapeutics Q3 2025: A mixed quarter with a significant earnings beat and strong cash position, but revenue missed estimates and full-year guidance was lowered. 
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 7, 2025 ↗
 
Via Benzinga
News headline image
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Elastic, Applied Digital, Eightco Holdings And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
This Aptiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
BioMedNewsBreaks — Gyre Therapeutics (NASDAQ: GYRE) Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone
Via Investor Brand Network
News headline image
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker ↗
HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billion potential and strong fibrosis treatment pipeline. 
Via Benzinga
News headline image
This Actuate Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Gyre Therapeutics Inc.
Via GlobeNewswire
News headline image
MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
< Previous 1 2 3 4 Next >